Anti-ganglioside GD3 [KM8871]

Absolute Antibody

Anti-ganglioside GD3 [KM8871]

7

KM8871 recognizes ganglioside GD3, a prominent ganglioside of human melanoma, melanocytes and other cells of neuroectodermal origin. It cross-reacted weakly with GQ1b.

Ganglioside G3 is one of the major gangliosides expressed on most human cancers of neuroectodermal and epithelial origin and is a potential target for passive immunotherapy with monoclonal antibodies. This clone (KM8871) is recommended for the research and development of potential therapeuic agents for immunotherapy and target validation of ganglioside-based vaccine therapy (Nakamura et al., 2001; pmid: 11499811). The potent binding of the humanized antibody KM8871 to the ganglioside GD3 was confirmed by ELISA testing (Nakamura et al., 2001; pmid: 11499811). It was also demonstrated that KM8871 was able to induce CDC (complement-dependent cytotoxicity) and strong ADCC (antibody-dependent cellular cytotoxicity) against ganglioside GD3-expressing cancer cells (Nakamura et al., 2001; pmid: 11499811). Consequently, this humanized antibody can be further investigated as a potential therapetic candidate against various neuroectodermal and epithelial cancers, either alone or with active molecules conjugated to it.

ELISA, Neutralisation/Blocking

Therapeutics development; neutralizing; ELISA

Research Use Only

Monoclonal

KM8871

Mouse

IgG3

Human

Human

This antibody was originally raised as a mouse IgG3 (clone KM641) which was turned into a mouse/human chimeric antibody KM871 and, finally, humanized by complementarity-determining region grafting and designated as KM8871 (Shitara et al., 1993; pmid: 8500110; Nakamura et al., 2001; pmid: 11499811).

-20°C,2°C to 8°C

12352203